Platinum doublet vs non‐platinum therapy
Overall survival · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to lower overall survival compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
- Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable… 2023 · Cochrane Headline outcomes onlyHR 0.67 [0.57, 0.78]7 studies · 697 participantsModerate